{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:28:39Z","timestamp":1792319319981,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010564","name":"Deutsche Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","award":["DZL;82DZL001A5"],"award-info":[{"award-number":["DZL;82DZL001A5"]}],"id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["rafo 174292"],"award-info":[{"award-number":["rafo 174292"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6berg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene amplification is considered to be one responsible cause for upregulation of Programmed Death Ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC) and to represent a specific molecular subgroup possibly associated with immunotherapy response. Our aim was to analyze the frequency of PD-L1 amplification, its relation to PD-L1 mRNA and protein expression, and to characterize the immune microenvironment of amplified cases. The study was based on two independent NSCLC cohorts, including 354 and 349 cases, respectively. Tissue microarrays were used to evaluate PD-L1 amplification by FISH and PD-L1 protein by immunohistochemistry. Immune infiltrates were characterized immunohistochemically by a panel of immune markers (CD3, CD4, CD8, PD-1, Foxp3, CD20, CD138, CD168, CD45RO, NKp46). Mutational status was determined by targeted sequencing. RNAseq data was available for 197 patients. PD-L1 amplification was detected in 4.5% of all evaluable cases. PD-L1 amplification correlated only weakly with mRNA and protein expression. About \u00a037% of amplified cases were negative for PD-L1 protein. PD-L1 amplification did not show any association with the mutational status. In squamous cell cancer, PD-L1 amplified cases were enriched among patients with high tumoral immune cell infiltration and showed gene expression profiles related to immune exhaustion. In conclusion, PD-L1 amplification correlates with PD-L1 expression in squamous cell cancer and was associated with an immune cell rich tumor phenotype. The correlative findings help to understand the role of PD-L1 amplification as an important immune escape mechanism in NSCLC and suggest the need to further evaluate PD-L1 amplification as predictive biomarker for checkpoint inhibitor therapy.<\/jats:p>","DOI":"10.1007\/s00262-020-02825-z","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T11:04:00Z","timestamp":1613127840000},"page":"2577-2587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung"],"prefix":"10.1007","volume":"70","author":[{"given":"Torsten","family":"Goldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rte","family":"Nitschkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Krupar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Elfving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Thurfjell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea","family":"La Fleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Mezheyeuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Sofia Margareta","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7256","authenticated-orcid":false,"given":"Carina","family":"Strell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"2825_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124\u2013128. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"key":"2825_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"key":"2825_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02613-9","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tiseo M, Banna GL et al (2020) Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265 50%. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-020-02613-9","journal-title":"Cancer Immunol Immunother"},{"key":"2825_CR4","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","volume":"37","author":"I Zerdes","year":"2018","unstructured":"Zerdes I, Matikas A, Bergh J et al (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37:4639\u20134661. https:\/\/doi.org\/10.1038\/s41388-018-0303-3","journal-title":"Oncogene"},{"key":"2825_CR5","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00262-018-2226-9","volume":"67","author":"Y Shi","year":"2018","unstructured":"Shi Y (2018) Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immunother 67:1481\u20131489. https:\/\/doi.org\/10.1007\/s00262-018-2226-9","journal-title":"Cancer Immunol Immunother"},{"key":"2825_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/modpathol.2017.156","volume":"31","author":"JM Taube","year":"2018","unstructured":"Taube JM, Galon J, Sholl LM et al (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214\u2013234. https:\/\/doi.org\/10.1038\/modpathol.2017.156","journal-title":"Mod Pathol"},{"key":"2825_CR7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/modpathol.2017.86","volume":"30","author":"M Chen","year":"2017","unstructured":"Chen M, Andreozzi M, Pockaj B et al (2017) Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. Mod Pathol 30:1516\u20131526. https:\/\/doi.org\/10.1038\/modpathol.2017.86","journal-title":"Mod Pathol"},{"key":"2825_CR8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41379-019-0269-x","volume":"32","author":"S Gupta","year":"2019","unstructured":"Gupta S, Cheville JC, Jungbluth AA et al (2019) JAK2\/PD-L1\/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Mod Pathol 32:1344\u20131358. https:\/\/doi.org\/10.1038\/s41379-019-0269-x","journal-title":"Mod Pathol"},{"key":"2825_CR9","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268\u20133277. https:\/\/doi.org\/10.1182\/blood-2010-05-282780","journal-title":"Blood"},{"key":"2825_CR10","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-16-1069","volume":"23","author":"J George","year":"2017","unstructured":"George J, Saito M, Tsuta K et al (2017) Genomic amplification of CD274 (PD-L1) in small-cell lung cancer. Clin Cancer Res 23:1220\u20131226. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1069","journal-title":"Clin Cancer Res"},{"key":"2825_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/gcc.22365","volume":"55","author":"J Budczies","year":"2016","unstructured":"Budczies J, Bockmayr M, Denkert C et al (2016) Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274)\u2014associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer 55:626\u2013639. https:\/\/doi.org\/10.1002\/gcc.22365","journal-title":"Genes Chromosomes Cancer"},{"key":"2825_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/annonc\/mdv510","volume":"27","author":"T Goldmann","year":"2016","unstructured":"Goldmann T, Kugler C, Reinmuth N et al (2016) PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy. Ann Oncol 27:206\u2013207. https:\/\/doi.org\/10.1093\/annonc\/mdv510","journal-title":"Ann Oncol"},{"key":"2825_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/his.13339","volume":"72","author":"S Clav\u00e9","year":"2018","unstructured":"Clav\u00e9 S, Pijuan L, Casadevall D et al (2018) CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients. Histopathology 72:259\u2013269. https:\/\/doi.org\/10.1111\/his.13339","journal-title":"Histopathology"},{"key":"2825_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","volume":"11","author":"S Ikeda","year":"2016","unstructured":"Ikeda S, Okamoto T, Okano S et al (2016) PD-L1 Is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol 11:62\u201371. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.010","journal-title":"J Thorac Oncol"},{"key":"2825_CR15","doi-asserted-by":"publisher","first-page":"32113","DOI":"10.18632\/oncotarget.8528","volume":"7","author":"Y Inoue","year":"2016","unstructured":"Inoue Y, Yoshimura K, Mori K et al (2016) Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget 7:32113\u201332128. https:\/\/doi.org\/10.18632\/oncotarget.8528","journal-title":"Oncotarget"},{"key":"2825_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/PAI.0000000000000235","volume":"24","author":"L Tran","year":"2016","unstructured":"Tran L, Mattsson JSM, Nodin B et al (2016) Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol 24:648\u2013659. https:\/\/doi.org\/10.1097\/PAI.0000000000000235","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2825_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jtho.2016.01.020","volume":"11","author":"P Micke","year":"2016","unstructured":"Micke P, Mattsson JSM, Djureinovic D et al (2016) The impact of the fourth edition of the WHO classification of lung tumours on histological classification of resected pulmonary NSCCs. J Thorac Oncol 11:862\u2013872. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.020","journal-title":"J Thorac Oncol"},{"key":"2825_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/1078-0432.CCR-12-1139","volume":"19","author":"J Botling","year":"2013","unstructured":"Botling J, Edlund K, Lohr M et al (2013) Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19:194\u2013204. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1139","journal-title":"Clin Cancer Res"},{"key":"2825_CR19","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1097\/JTO.0b013e3182295917","volume":"6","author":"P Micke","year":"2011","unstructured":"Micke P, Edlund K, Holmberg L et al (2011) Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol 6:1833\u20131840. https:\/\/doi.org\/10.1097\/JTO.0b013e3182295917","journal-title":"J Thorac Oncol"},{"key":"2825_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/modpathol.2017.14","volume":"30","author":"M Grinberg","year":"2017","unstructured":"Grinberg M, Djureinovic D, Brunnstr\u00f6m HR et al (2017) Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Mod Pathol 30:964\u2013977. https:\/\/doi.org\/10.1038\/modpathol.2017.14","journal-title":"Mod Pathol"},{"key":"2825_CR21","doi-asserted-by":"publisher","first-page":"e86837","DOI":"10.1172\/jci.insight.86837","volume":"1","author":"D Djureinovic","year":"2016","unstructured":"Djureinovic D, Hallstr\u00f6m BM, Horie M et al (2016) Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight 1:e86837. https:\/\/doi.org\/10.1172\/jci.insight.86837","journal-title":"JCI Insight"},{"key":"2825_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","volume":"130","author":"L La Fleur","year":"2019","unstructured":"La Fleur L, Falk-S\u00f6rqvist E, Smeds P et al (2019) Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer 130:50\u201358. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.003","journal-title":"Lung Cancer"},{"key":"2825_CR23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243\u20131260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"2825_CR24","doi-asserted-by":"publisher","first-page":"26483","DOI":"10.18632\/oncotarget.4494","volume":"6","author":"MT Barrett","year":"2015","unstructured":"Barrett MT, Anderson KS, Lenkiewicz E et al (2015) Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6:26483\u201326493. https:\/\/doi.org\/10.18632\/oncotarget.4494","journal-title":"Oncotarget"},{"key":"2825_CR25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Piccioni D, Kato S et al (2018) Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol 4:1237\u20131244. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1701","journal-title":"JAMA Oncol"},{"key":"2825_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","volume":"66","author":"N Chen","year":"2017","unstructured":"Chen N, Fang W, Lin Z et al (2017) KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother 66:1175\u20131187. https:\/\/doi.org\/10.1007\/s00262-017-2005-z","journal-title":"Cancer Immunol Immunother"},{"key":"2825_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","volume":"66","author":"R Okita","year":"2017","unstructured":"Okita R, Maeda A, Shimizu K et al (2017) PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother 66:865\u2013876. https:\/\/doi.org\/10.1007\/s00262-017-1986-y","journal-title":"Cancer Immunol Immunother"},{"key":"2825_CR28","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/2211-5463.12568","volume":"9","author":"X Li","year":"2019","unstructured":"Li X, Wang Z, Huang J et al (2019) Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression. FEBS Open Bio 9:1063\u20131070. https:\/\/doi.org\/10.1002\/2211-5463.12568","journal-title":"FEBS Open Bio"},{"key":"2825_CR29","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1111\/1759-7714.13653","volume":"11","author":"S Katakura","year":"2020","unstructured":"Katakura S, Kobayashi N, Hashimoto H et al (2020) MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer. Thorac Cancer 11:2975\u20132982. https:\/\/doi.org\/10.1111\/1759-7714.13653","journal-title":"Thorac Cancer"},{"key":"2825_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-1536-x","author":"H Wang","year":"2020","unstructured":"Wang H, Fu C, Du J et al (2020) Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-020-1536-x","journal-title":"J Exp Clin Cancer Res"},{"key":"2825_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-19-0855","volume":"8","author":"C-C Balan\u00e7a","year":"2020","unstructured":"Balan\u00e7a C-C, Scarlata C-M, Michelas M et al (2020) Dual relief of T-lymphocyte proliferation and effector function underlies response to PD-1 blockade in epithelial malignancies. Cancer Immunol Res 8:869\u2013882. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0855","journal-title":"Cancer Immunol Res"},{"key":"2825_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"2825_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cllc.2019.02.012","volume":"20","author":"H Elfving","year":"2019","unstructured":"Elfving H, Mattsson JSM, Lindskog C et al (2019) Programmed Cell death ligand 1 immunohistochemistry: a concordance study between surgical specimen, biopsy, and tissue microarray. Clin Lung Cancer 20:258-262.e1. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.012","journal-title":"Clin Lung Cancer"},{"key":"2825_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41379-019-0383-9","volume":"33","author":"E Thunnissen","year":"2020","unstructured":"Thunnissen E, Kerr KM, Dafni U et al (2020) Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays\u2019 and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Mod Pathol 33:792\u2013801. https:\/\/doi.org\/10.1038\/s41379-019-0383-9","journal-title":"Mod Pathol"},{"key":"2825_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","volume":"33","author":"E Torlakovic","year":"2020","unstructured":"Torlakovic E, Lim HJ, Adam J et al (2020) \u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol 33:4\u201317. https:\/\/doi.org\/10.1038\/s41379-019-0327-4","journal-title":"Mod Pathol"},{"key":"2825_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12885-020-06785-6","volume":"20","author":"EMP Steeghs","year":"2020","unstructured":"Steeghs EMP, Kroeze LI, Tops BBJ et al (2020) Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer 20:291. https:\/\/doi.org\/10.1186\/s12885-020-06785-6","journal-title":"BMC Cancer"},{"key":"2825_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jmoldx.2013.08.004","volume":"16","author":"CC Pritchard","year":"2014","unstructured":"Pritchard CC, Salipante SJ, Koehler K et al (2014) Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 16:56\u201367. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.08.004","journal-title":"J Mol Diagn"},{"key":"2825_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","volume":"25","author":"DG Rothwell","year":"2019","unstructured":"Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25:738\u2013743. https:\/\/doi.org\/10.1038\/s41591-019-0380-z","journal-title":"Nat Med"},{"key":"2825_CR39","doi-asserted-by":"publisher","first-page":"e0187246","DOI":"10.1371\/journal.pone.0187246","volume":"12","author":"V Jabs","year":"2017","unstructured":"Jabs V, Edlund K, K\u00f6nig H et al (2017) Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS ONE 12:e0187246. https:\/\/doi.org\/10.1371\/journal.pone.0187246","journal-title":"PLoS ONE"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02825-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:06:50Z","timestamp":1628770010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02825-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2825"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02825-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethical Review Board in Uppsala (Ref 2006\/325 and 2012\/532) and was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The ethical approval covers usage of the clinical data in retrospective studies without informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}